HAS3 and breast carcinoma: This has been shown in human chondrosarcoma, HAS3 overexpressing MCF7 breast cancer (Rilla et al., 2013), melanoma cells (Arasu et al., 2019; Deen et al., 2016), and HAS3 overexpressing MCF10A cells (Noble et al., 2020).